

Advances in Antimicrobial  
and Antineoplastic Chemotherapy

Volume I/2

# Advances in Antimicrobial and Antineoplastic Chemotherapy

Progress in Research and Clinical Application

Proceedings of the VII<sup>th</sup> International Congress  
of Chemotherapy Prague, 1971

Editors Miroslav Hejzlar, Prague  
Miroslav Semonský, Prague  
Stanislav Masák, Prague

## Editorial Board

Hans Ericson, Stockholm  
Georgij F. Gause, Moscow  
Helmut Paul Kuemmerle, Munich  
George M. Ling, Ottawa  
Prokop Málek, Prague  
Hamao Umezawa, Tokyo

Volume 1/2: Antimicrobial Chemotherapy 2

395 Figures and 438 Tables

University Park Press • Baltimore - London - Tokyo 1972

## Contents of Volume I/2

### Laboratory Control of Chemotherapy

<i>G. Anderson</i> : The Role of the Laboratory in Antimicrobial Therapy . . . . .	681
<i>Y. Kanazawa</i> and <i>T. Kuramata</i> : Application of Sensitivity Discs to Some Clinical Laboratory Tests for Chemotherapy . . . . .	685
<i>J. Zangger</i> : Antibiotic Sensitivity Tests with Multodisk <sup>R</sup> . . . . .	689
<i>G. N. Rolinson</i> and <i>Elizabeth J. Russell</i> : A New Routine Antibiotic Sensitivity Test . . . . .	691
<i>H. Hlava</i> : Improved Routine Method in the Study of Antibiotic Interaction . . . . .	693
<i>T. Charizanova</i> and <i>V. Simova</i> : Microbiological Method for Determination of INH in the Urine . . . . .	697
<i>B. Lynn</i> and <i>A. Jones</i> : Interactions between Penicillins and Aminoglycoside Antibiotics in Parenteral Solution . . . . .	701
<i>O. O. Makejeva</i> : The Action of Several Antituberculous Drugs upon Development of Drug Resistance of <i>M. tuberculosis</i> to Isoniazid . . . . .	707
<i>T. P. Radkevitch</i> , <i>R. A. Stasjonok</i> and <i>E. A. Rudzil</i> : Comparative Study of Antistaphylococcal Activity of Semisynthetic Penicillins . . . . .	709
<i>L. J. Bononi</i> and <i>G. Renzini</i> : Microbiological Properties of Carbenicillin . . . . .	711
<i>Ž. Žagar</i> : Kinetics of Antibacterial Inhibition Power of Ampicillin, Cloxacillin, Carbenicillin and Gentamicin at Changing Concentration Similar to That in the Body Fluids . . . . .	715
<i>E. Helm</i> and <i>W. Stille</i> : Kinetics of Bactericidal Action of Carbenicillin, Gentamicin and Polymyxin B against <i>Pseudomonas aeruginosa</i> . . . . .	719
<i>K. Ubukata</i> , <i>R. Fujii</i> and <i>M. Konno</i> : The Filamentous Shape of <i>Pseudomonas aeruginosa</i> and Its Phagocytal Formation by Leukocytes Observed in the Urine of a Child Having Pyelonephritis under Treatment with Carbenicillin . . . . .	723
<i>I. P. Fomina</i> , <i>S. M. Kuznetsova</i> , <i>S. M. Navashin</i> and <i>E. M. Sergeyuk</i> : Comparative Sensitivity to Cephaloridine and Semi-Synthetic Penicillins of Clinical Strains of Bacteria Causing Purulent Infections . . . . .	727
<i>G. Velluti</i> : <i>In Vitro</i> Activity of Gentamicin against Several Bacterial Species and Mycobacteria . . . . .	731
<i>A. Sanna</i> , <i>G. Ambrosoli</i> , <i>M. G. Menozzi</i> , <i>M. P. Ciuli</i> and <i>A. Turano</i> : <i>In Vitro</i> Activity of Gentamicin . . . . .	735
<i>M. L. Zaremba</i> , <i>D. Dzierżanowska</i> , <i>E. Jereczek-Morawska</i> , <i>B. Stefańska</i> , <i>M. Bobrowski</i> , <i>J. Borowski</i> and <i>E. Borowski</i> : <i>In Vivo</i> Laboratory Studies on Phosphonomycin . . . . .	739
<i>V. Tchavdarova</i> , <i>T. Charizanova</i> , <i>G. Sheikova</i> , <i>Y. Georgieva</i> , <i>B. Vassileva</i> and <i>A. Nakov</i> : Comparative Study of Carbenicillin and Gentamicin, and Other Broad-Spectrum Antibiotics . . . . .	741
<i>I. Phillips</i> and <i>Christine Warren</i> : Antibiotic Sensitivity of Oral Streptococci Following Penicillin, and of Streptococci Causing Endocarditis . . . . .	745
<i>R. N. Grüneberg</i> : The Choice of Treatment for Urinary Infection According to the Sensitivities of the Causative Organisms . . . . .	749
<i>I. Mortensen</i> , <i>V. Frølund Thomsen</i> and <i>M. Weis Bentzon</i> : The Bactericidal Effect of a Combination of Sulphamethoxazole and Trimethoprim . . . . .	751
<i>E. Přebáň</i> , <i>J. Buda</i> , <i>D. Janovská</i> , <i>Z. Jedličková</i> , <i>V. Rotreli</i> and <i>F. Výmola</i> : Schedule for Rational Administration of Some Penicillin Preparations and Trimethoprim A Sulphonamide Potentiator . . . . .	755
<i>R. Gallien</i> : Studies on Bactericidal Efficacy of Trimethoprim/Sulfamethoxazol . . . . .	757
<i>Ö. Anđ</i> and <i>K. Töreci</i> : Trimethoprim-Sulphamethoxazole Susceptibility of Pathogenic Bacteria Isolated in Istanbul . . . . .	761

<i>J. C. Cale: Isolation of Serratia marcescens from Stools with an Antibiotic Plate</i>	763
<i>A. Lassus and E. Jansson: In Vitro Sensitivity of T-Strain Mycoplasmas to Antibiotics</i>	765
<i>R. Gomez-Lus and A. Sarria Chueca: The Use of Microculture with Fluorescent Antibody (MFA) in the Diagnosis and Treatment of Whooping-Cough</i>	769
<i>H. Felix, M. Mora, M. Castels, J. Duval and Ch. Lafaix: Application of Sulfamethoxazole-Trimethoprim in Treatment of Shigellosis</i>	773
<i>B. Bandur, L. Novaković and S. Popović: The Influence of Antibacterial Chemotherapy on Serum Antibody-Titer Levels in Urinary Tract Infections</i>	777

## Mode of Antibiotic Action

<i>Z. Vaněk: Arrival of Biogenetically Tailored Antibiotics</i>	783
<i>I. Rychlík and J. Černá: Effect of Macrolide Antibiotics on Ribosomal Peptidyl Transferase</i>	793
<i>S. Pestka: Effect of Antibiotics on Peptidyl-Puromycin Formation in Polyribosomes and a Model of Ribosome Function</i>	797
<i>E. Ballaner and D. Vazquez: Subunit and Site of Action of Some Inhibitors Acting on 80 S Type Ribosomes</i>	801
<i>C. Coulsogeorgopoulos: Kinetics of Inhibition of Peptide Chain Elongation</i>	803
<i>M. A. Cousin, M. P. de Garilhe, F. Gros and D. Lando: Basic Differences in the Mechanism of Action of the Aminoglycoside Antibiotics</i>	807
<i>C. Hurwitz and C. L. Rosano: Effects of Puromycin on the Lethal Action of Dihydrostreptomycin</i>	809
<i>P. Knolle: Rifampicin-Sensitivity of RNA Bacteriophage-Specific Polysome Formation</i>	813
<i>E. Gravela, R. Di Carlo, F. Di Carlo and E. Genazzani: Studies on the Triacetyloleandomycin Liver Steatosis: Protein Synthesis</i>	817
<i>H. Thrum, I. Haupt, G. Bradler, Ch. Zimmer and K. E. Reinert: Netropsin and Distamycin A: Relations between Antibiotic Properties, Action on Nucleic Acid and Protein Biosynthesis in Vivo, and Interaction with Nucleic Acids in Vitro</i>	819
<i>H. Grunicke, B. Puschendorf, E. Petersen, H. Wolf and H. Werchau: Studies on the Effect of Distamycin A on the DNA Dependent RNA Polymerase Reaction</i>	823
<i>F. E. Hahn and A. K. Krey: Complex of DNA with the Antibiotic Distamycin A</i>	825
<i>G. Fey and H. Kersten: Fluorescence Analysis of Tetracycline Binding to Ribosomes</i>	827
<i>K. Mikulík, N. Quyen, J. Tax and J. Kárnělová: Binding Interaction of Tetracycline with Ribosomes</i>	833
<i>J. V. Dudnik: The Effect of Some Antitumor Antibiotics in Systems with Distorted Repair of DNA</i>	839
<i>G. H. Hitchings: Biochemical Basis for the Antibacterial Activity of TMP-SMX (Septrin)</i>	843
<i>S. R. M. Bushby: Effects of Sulfonamides on the Emergence of Trimethoprim-Resistant Variants</i>	847
<i>T. Perényi, L. Biró, É. Iván and M. Árr: In Vitro Hydrolysis of Acetoxy-Methyl-Benzyl-Penicillin</i>	849
<i>F. Di Carlo, R. Di Carlo, P. Martinello, G. Cavallo and E. Genazzani: Increase of Triacetyloleandomycin (TAO) Therapeutic Index by Cysteine</i>	851
<i>F. Piccinini, A. Chiarra and F. Villani: Effect of Terpenes on the Cell Permeability to Tetracycline</i>	855
<i>L. Falkowski, A. Malula and E. Borowski: Effect of Polyene Macrolide Antibiotics on Permeability of Liposomes</i>	859
<i>V. Lorian and B. Popoola: A New Staphylococcal Hemolysin Produced with Antibiotics</i>	861
<i>A. Goudot: Chemical Structure of Antimetabolites and Antibiot Action</i>	863

M. Espinosa, J. M. Lopez Martinez, R. Lopez and A. Portoles: Pigmentation Differences in Pathogenic <i>Pseudomonas aeruginosa</i> Strains in Relation to Different Antibiotic Actions	865
P. Nemec, L. Drobnica, J. Augustin, Ž. Odlerová and O. Ondrejčková: Specific Antimycobacterial Activity of Aromatic Isothiocyanates of the Cumulated System	867
L. Ebringer, A. Jurášek, P. Krkoška, R. Kada and P. Follínová: New Nitrofurans — A Correlation Study between Chemical Structures and Biological Activity	873
N. E. Klimova, L. M. Jacobson and A. S. Konikova: The Influence of Oleandomycin on the Process of Embryonic Protein Synthesis Studied by means of a Radioactive Label	877
F. Šmejkal, Z. Buděšínský, J. Sluka and M. Kuchař: Study of Antiviral Activity of Some Adamantane, Pyrimidine and Isatine Analogs	879
B. Rada and J. Žemla: Virus Replication and de Novo Pyrimidine Biosynthesis	885

## Experimental Chemotherapy

G. N. Rolinson: Experimental Chemotherapy in Relation to Clinical Effect of Antibiotics	891
R. R. Ledbetter, Mary D. Blizzard, W. Ritter and R. F. Krueger: Effect of Burn Temperature on the Mortality and Chemotherapy of <i>Pseudomonas aeruginosa</i> Infected Mice	897
J. A. Raeburn: Antibiotics and the Inflammatory Response	901
A. Kleinschmidt, K. Sack, H. G. Koch and R. Commichau: New Model of Experimental Coli-Pyelonephritis in Rats for Therapeutic Studies	905
H. Loew, W. Ritzlerfeld and H. Christ: The Influence of Chemotherapy on the Serum Antibody Response to <i>E. coli</i> in Rabbits with Experimental Pyelonephritis	907
V. Prál, L. Kontčková and M. Hatala: Course and Chemotherapy of Experimental <i>E. coli</i> Infections of Urinary Tract at Various Degrees of Diuresis	911
M. Okui, T. Matsubara, M. Nishida and J. Kozatani: Metabolic Studies on Cefazolin- <sup>14</sup> C in Laboratory Animals	915
M. Brunaud and J. Vindel: Pharmacokinetics of Polymyxin Methyl Sulfonic Acid in the Rat	919
P. Hlavatý, J. Augustin, J. Maťoška and E. Drobnica: Observation of the Resorption and Topographic Distribution of 4-Bromophenylisothiocyanate- <sup>35</sup> S on Normal Guinea-Pig Skin in Various Bases	923
W. Brumfitt: The Assessment of New Antimicrobial Agents	927
I. Selnikar, L. Degen, E. Massarani and D. Nardi: Nifurpipone - A New Nitrofurans for Urinary Tract Infections	931
L. Kontčková, V. Prál, W. Ritzlerfeld and M. Hatala: Nitrofurantoin-Sulfadiazine Combination in Experimental <i>E. coli</i> Infections of Urinary Tract	935
L. I. Lisitsa and E. A. Rudzil: Experimental Therapy of Pyelonephritis Produced by <i>E. coli</i> in Rats	939
R. Preuner, H. Freisleben, H. G. Koch and W. Henkel: Experimental Chemotherapy of Non-Obstructive <i>Escherichia coli</i> Pyelonephritis in Rats	943
Z. V. Ermolieva, E. A. Vedmina, I. V. Vlasova, N. I. Givental, V. R. Sobolev, I. N. Krasnova, L. O. Popova and A. E. Libenzon: Study of the Effectiveness of Antibiotics in Experimental Infection Caused by Cholera and Cholera-Like Vibrios	947
M. Plempel and K. Bartmann: New Experimental Data on the Oral Antimycotic Clotrimazole	949
Elaine Barrett and A. W. Asscher: Potentiation of Effect of Carbenicillin on <i>Pseudomonas aeruginosa</i> by Ethylenediaminetetra-Acetic Acid (E. D. T. A.)	953
I. de Carneri, G. Monli, A. Bianchi, V. Mandelli and V. Tamassia: Studies on the Synergism of a Combination of Chloramphenicol and Tetracycline in Experimental Infections	955

<i>E. Genazzani, L. J. Bononi, D. Savoia, F. Di Carlo and U. Cellerino: Synergistic Action of Two Penicillins</i> . . . . .	959
<i>E. Killnar, F. Výmola, M. Hejzlar, O. Lochmann and A. Povolná: Influence of Gentamicin and Carbenicillin on the Course of Experimental Infection by Pseudomonas, Proteus and Staphylococcus organisms</i> . . . . .	963

## New Antibacterial Antibiotics

<i>A. S. Khokhlov: Today's Position of Antibiotics and Their Derivatives</i> . . . . .	967
<i>P. Acred, Pamela A. Hunter and Linda Mizen: Antibacterial Activity and Blood Levels of <math>\alpha</math>-Amino-p-Hydroxybenzyl Penicillin (BRL 2333), A New Semi-synthetic Penicillin, in Experimental Animals</i> . . . . .	969
<i>E. A. P. Croydon and R. Sutherland: Microbiology and Human Pharmacology of Amoxycillin (BRL 2333)</i> . . . . .	975
<i>A. M. Geddes, J. D. Williams, J. Kosmidis, J. A. D. Goodall and J. Andrews: Clinical Pharmacological Studies with a New Semisynthetic Penicillin, Alpha-Amino-p-Hydroxy-Benzylpenicillin</i> . . . . .	981
<i>R. Sutherland, E. A. P. Croydon and G. N. Rolinson: Flucloxacillin — A New Semi-Synthetic Penicillin</i> . . . . .	985
<i>G. P. Bodey: Clinical Pharmacology of Orally Administered Flucloxacillin</i> . . . . .	991
<i>Éva Iván, L. Biró, M. Árr and T. Perényi: Clinico-Pharmacological Investigation of Acetoxy-Methyl-Ester of Benzyl-Penicillin</i> . . . . .	995
<i>Anna Uglešić and Ž. Žagar: Some New Semi-Synthetic Penicillins</i> . . . . .	997
<i>Ž. Žagar and Anna Uglešić: Antibacterial Properties of Some New Derivatives of 6-APA</i> . . . . .	1001
<i>M. Ohkoshi and Y. Naide: Clinical Aspects of Disodium Alpha-Sulfobenzyl Penicillin — A New Synthetic Penicillin</i> . . . . .	1005
<i>S. Ishiyama, I. Nakayama, H. Iwamoto and S. Iwai: Absorption and Distribution of <math>^{14}\text{C}</math>-Sulfobenzyl-penicillin</i> . . . . .	1011
<i>E. Csányi and I. Elekes: Pharmacokinetic Studies with Pirazocillin—A New Semi-synthetic Penicillin Derivative</i> . . . . .	1015
<i>A. R. English and J. E. Lynch: Preclinical Studies with an Orally Effective Form of Carbenicillin — Carbenicillin Indanyl Sodium (CP-15, 464—2)</i> . . . . .	1019
<i>A. J. Birch: Partial Synthesis of Some Novobiocin Analogues</i> . . . . .	1023
<i>K. Eckardt, G. Bradler, D. Tresselt and H. Fritzsche: Studies on Resistoflavin — A New Antibiotic of the Resistomycin Family</i> . . . . .	1025
<i>L. I. Torbochkina, Ye. V. Bobikov, Yu. O. Sazykin, G. B. Lokshin, Yu. V. Zhdanovich and A. D. Kuzovkov: Production of <math>^{14}\text{C}</math>-Mithramycin Using Various Precursors</i> . . . . .	1029
<i>N. Porowska, L. Halski, Z. Plóciennik, D. Koliuszko, H. Morawska, Z. Kowszyk-Gindifer and H. Bojarska-Dahlig: Components of Polifungin — A New Antifungal Antibiotic Complex</i> . . . . .	1031
<i>S. Againa and I. Ognyanov: Study on the Chemistry of the Antifungal Antibiotic Niphimycin</i> . . . . .	1035
<i>A. Nagata, T. Ando, T. Noda, T. Take and K. Hayano: Tuberactinomycin-N—A New Tuberactinomycin Family Antibiotic</i> . . . . .	1039
<i>J. Borowski, E. Borowski, M. Bobrowski, D. Dzierżanowska, P. Jakubicz and T. Ziemiński: In Vitro Studies of Phosphonomycin, A New Broad-Spectrum Antibiotic</i> . . . . .	1043
<i>D. K. Zhelyazkov, N. M. Gueorguiev, A. Belcheva, M. Mangurova, N. D. Temnjalov, G. I. Yakimov, D. Markov and R. Marinova: On the Pharmacotoxicological Characterization of a New Broad-Spectrum Antibiotic Gentamicin</i> . . . . .	1047
<i>W. J. Holloway and J. L. Clark: Preliminary Report on AV 290</i> . . . . .	1051

M. Kurita, T. Teraji, Y. Sailo, H. Harada, K. Hallori, T. Kamiya, M. Nishida and T. Takano: Structure-Activity Studies in Semi-Synthetic Cephalosporins'	1055
H. H. Gadebusch, G. J. Miraglia, H. I. Basch, C. Goodwin, S. Pan and K. Renz: Cephadrine — A New Orally Absorbed Cephalosporin Antibiotic	1059
W. Zimmermann, F. Knüsel and A. Rosselet: The Lytic and Bactericidal Effect of Derivatives of 7-Cyanacetamido-Cephalosporanic Acid	1063
S. Nakazawa, H. Salo and Y. Nakaji: Studies on Cefazolin — A New Semi-Synthetic Cephalosporin, in the Field of Pediatrics	1067
P. Gantes, J. C. Bouchillé and F. Méry: Apesporine — An Experimental Polymyxin Derivative	1069
J. Wieriks: Animal Reactions to, and Tolerance of, Two Local Anesthetic-Free Tetracycline Preparations Injected by Various Routes	1071
S. Nakasawa, H. Salo, Y. Mochizuki and Y. Nakachi: Clinical Studies on Piromidic Acid in the Field of Pediatrics	1075
H. Loewe, J. Urbanietz, E. Schrinner and W. Bonin: New Antibacterial Derivatives of 2,6-Bis-Benzimidazole	1079
G. Malesani, F. Marcolin and G. Rodighiero: Synthesis and Antimicrobial Activity of Some New 8-Hydroxy-Quinazoline Compounds	1081
Ž. Odlerová, J. Augustin and P. Nemec: Antituberculotic Action of 3,5-Disubstituted Tetrahydro-1,3,5-Thiadiazine-2-Thiones	1085
N. V. Pokidova, T. P. Zhuravleva, S. S. Babayan and Z. V. Ermolieva: Chemical and Biological Characteristics of Human Lysozyme Isolated from Placenta	1089
K. Tsuchiya, T. Yamazaki, T. Oishi, C. Iwagishi, T. Iwahi, S. Kuwahara and S. Goto: <i>In Vitro</i> and <i>in Vivo</i> Antibacterial Activity of Disodium $\alpha$ -Sulfobenzylpenicillin, A New Semi-Synthetic Penicillin	1091
A. D. Russell: Laboratory Studies on a New Cephalosporin, CIBA 36, 278-Ba	1095

## Clinical Evaluation of Antibacterial Chemotherapeutics in Internal Medicine

E. Jawetz: Clinical Evaluation of Antimicrobial Drugs	1101
D. T. D. Hughes, A. Bye and P. Hodder: Levels of Trimethoprim and Sulphamethoxazole in Blood and Sputum in Relation to Treatment of Chest Infections	1105
L. Biró, É. Iván, T. Perényi and M. Árr: Clinico-Pharmacological and Experimental Investigations with Trimethoprim and Sulphonamid Combinations	1107
G. K. Daikos, S. Kastanakis, A. E. Haljivasiliou and A. Ionnidou: Cerebrospinal Fluid Levels of Trimethoprim	1109
K. Naficy, R. A. Gharagozloo, M. Mouin, M. H. Nassirzadeh and R. Yalda: Comparative Trial of Tetracycline, Chloramphenicol and Trimethoprim/Sulphamethoxazole in Eradication of <i>Vibrio cholerae</i> El Tor and Effect of Purging on Reappearance of the Organism	1111
T. Yamamoto: Response of Enteric Bacterial Infections to Chemotherapeutic Agents in Japan	1115
H. Pichler and K. H. Spitz: Trimethoprim-Sulphamethoxazole in the Treatment of Typhoid Carriers or Para-Typhoid Carriers	1119
R. A. Gharagozloo, K. Naficy, K. Badalian, A. Najafian, R. Salimpour, P. Vosough and B. Hedayati: Effects of a Trimethoprim/Sulphamethoxazole Combination on the Clinical Course and Elimination of Faecal Pathogens in Bacterial Enteritis	1123
B. Hernández Carbajal: Treatment of Chronic Osteomyelitis with Bactrim and the Ambulatory Method	1127
I. Lenox-Smith, G. M. Clarke and G. Johnston: Low Dose Prophylaxis of Chronic Bronchitis with Trimethoprim-Sulphamethoxazole (Bactrim): A Comparison with Low-Dose Clomocycline	1129

<i>Marianne Faehlmann and R. Lundström: Doxycycline and Erythromycin in Acute Lower Respiratory Infections . . . . .</i>	1131
<i>B. Raška, A. Rubin and L. Hradcová: Experience with Doxycycline Therapy in Children . . . . .</i>	1133
<i>J. Havlík, J. Tesařová-Mádrová and A. Kollová: Doxycycline and Methacycline Syrup Treatment of Respiratory Complications of Measles . . . . .</i>	1137
<i>D. Kabbage and R. Nicol: Doxycycline in Staphylococcus Septicemias . . . . .</i>	1139
<i>F. Londono and J. H. Reyes: Doxycycline in Treatment of Lepromatous Leprosy . . . . .</i>	1141
<i>F. W. Ogden: Single-Dose Doxycycline Treatment of Epidemic Louse-Borne Typhus: Preliminary Communication . . . . .</i>	1143
<i>M. M. Joseph: Comparative Study of the Efficacy of Procaine Penicillin and Intravenous Doxycycline (Vibravenous) in the Treatment of Anthrax: Preliminary Communication . . . . .</i>	1145
<i>T. Dimmling, M. Schoog, E. Winkler and H. Weih: Experience with Doxycycline Intravenous Ready for Injection . . . . .</i>	1147
<i>M. Schoog, E. Winkler and H. Weih: Clinical Studies with Doxycycline Intravenous Ready for Injection . . . . .</i>	1149
<i>Ch. Tauchnitz and Maria Horn: Carriers of S. typhi and S. paratyphi B: Therapeutic Effect of the Synergistic Bactericidal Combination Ampicillin and Kanamycin . . . . .</i>	1151
<i>N. Papadoyanakis, C. Roussos and X. Kontomichalou: Clinical Experience with Minocycline . . . . .</i>	1155
<i>D. Münnich: Experience with Nalidixic-Acid (Negram, Nevigramon) Treatment of Dysenteric Cases (Adults) . . . . .</i>	1159
<i>V. Boyanova, G. Sheikova, J. Doncheva, M. Kalushkova, V. Andreeva and S. Tchobanova: Clinical and Laboratory Study on Erythromycin Propionate Suspension for Children . . . . .</i>	1163
<i>G. Lepercq and R. Sleinschneider: Clinical Trial of Polymyxin Methylene Sulphonic Acid in Paediatrics . . . . .</i>	1165
<i>Z. Bakičová, V. Lipková and V. Krémery: Long-Term Follow-up of Antibiotic Administration to Children up to 3 Years of Age . . . . .</i>	1167
<i>L. Šlika, A. Pechar, B. Raška and L. Segethová: Consumption of Antibacterials as Recorded in Automated Processing of Medical Prescription in the District of Prague 6 . . . . .</i>	1171
<i>A. Saito, K. Noda, F. Matsumoto, K. Shiba and Y. Ueda: Clinical Evaluation of Cephalosporin Derivatives . . . . .</i>	1175
<i>K. Shiota, F. Miki, K. Mashimo, Y. Kato, K. Matsumoto, T. Nakamura, Y. Ueda, F. Matsumoto, A. Saito, H. Okubo, Y. Fujimoto and Y. Okamoto: Fundamental and Clinical Studies on Cefazolin . . . . .</i>	1179
<i>K. Nakagawa, J. Kabe, M. Katsu and S. Shimada: Comparative Studies of Cefazolin and Cephaloridine in Clinical Use in Patients with Bacterial Pneumonia . . . . .</i>	1183
<i>G. K. Daikos, A. Katrahoura-Ioannidis, S. Zellos and Z. Kalams: Clinical Evaluation of a New Cephalosporin, Cephapirin . . . . .</i>	1185
<i>N. Cho, (Chang), T. Ito, T. Saito and M. Fukada: Studies on Cefazolin in Obstetrics and Gynecology with Special Reference to Its Clinical Pharmacology in the Neonate . . . . .</i>	1187
<i>A. N. Walker, P. D. Fairclough and D. Geraint James: Clinical and Laboratory Experience with Cephalexin . . . . .</i>	1191
<i>D. W. Gump: The Treatment of Staphylococcal Osteomyelitis with Cephalexin . . . . .</i>	1195
<i>C. H. Dash, R. D. Foord, Susan E. Johnson and P. F. Cooper: Cephalexin — A Later Clinical Appraisal . . . . .</i>	1199
<i>M. Salour: New Antibiotic in Treatment of Resistant Cases of Meningococcal Meningitis . . . . .</i>	1203
<i>Y. Kawamori: A Controlled Trial of the Clinical Effects of Chemotherapy with Rifampicin-INH-PAS for the Treatment of Original Case of Pulmonary Tuberculosis . . . . .</i>	1205

<i>A. M. Geddes, R. G. Finch, J. A. D. Goodall and J. E. Barker: The Treatment of Paediatric Infections with Clindamycin</i>	1207
<i>V. Vacek, M. Hejzlar, J. Štafová, J. Tesařová, M. Slavík and M. Syrovátková: Clinical and Laboratory Experience with Clindamycin</i>	1209
<i>B. Mariani, G. Velluti, A. Biselli and C. F. Marchioni: Gentamicin Activity on the Respiratory Tract Infections and on Asthmatic Bronchitis</i>	1211
<i>J. M. Alés Reinlein, A. Sastre Castillo and J. Vallejo Galbele: In Vitro Sensitivity of Gram-Negative Bacilli to Antibiotics. Gentamicin in Acute Respiratory Infections on Patients with Chronic Pneumopathies</i>	1215
<i>J. Štafová, V. Vacek, J. Tesařová and M. Syrovátková: Clinical Experience with Gentamicin in a Four-Years Period</i>	1217
<i>J. Lholák, B. Flašarová and H. Illava: Clinical Use of Ampiclox Neonatal</i>	1219
<i>I. Christov and G. Slavchev: Treatment of Perifocal Pneumonias in Cases of Lung Carcinoma</i>	1221
<i>J. Sternon, A. Cornil and A. Arana: Gentamicin and Staphylococcal Infections</i>	1223
<i>Ch. Lafair, J. C. Pechere, M. Zarouf, J. Pereira Africano Neto and M. Rey: Therapy of Bacterial Meningitis with Sulfamethoxazole-Trimethoprim</i>	1227
<i>G. Giunchi and F. de Rosa: Treatment of Acute Human Brucellosis due to <i>Br. melitensis</i> with Bactrim (Trimethoprim-Sulfamethoxazole Combination)</i>	1231
<i>H. Krekeler, G. v. Nieding, M. Schoog, U. Smidl, H. Weith and E. Winkler: The Influence of Intravenously Applied Tetracyclines on the Pulmonary and Circulatory Functions of Healthy Subjects and Patients with Chronic Bronchitis</i>	1233
<i>J. deVries, L. E. Francis and D. Lang: Clindamycin — A New Antibiotic for the Protection of the Cardiac Patient during Oral Surgery</i>	1237
<i>J. C. Sandeman and A. Percival: Fusidic Acid in the Management of Osteomyelitis</i>	1241
<i>R. Eckolt, H. Bürgi and J. Regli: Comparative Trial of Ampicillin and CIBA 36,278-Ba in Acute Exacerbations of Chronic Bronchitis</i>	1245
<i>P. Gordon and E. R. Brown: Isoprinosine (NPT-10381): Novel Biochemical Basis for Antiviral Action</i>	1247

## Clinical Evaluation of Antibacterial Chemotherapeutics in Surgery

<i>S. Ishiyama, I. Nakayama, H. Iwamoto and S. Iwai: Bacterial Endotoxin and Disseminated Intravascular Coagulation</i>	1253
<i>F. Výmola, J. Buda, O. Lochmann and J. Pillich: Position of Antibiotics in the Treatment of Chronic Surgical Infections</i>	1255
<i>E. Bodner and W. Schennach: Doxycycline i. v. in Various Infections at a Surgical Clinic</i>	1257
<i>S. Mizuno, S. Matsuda, M. Tanno and S. Mori: Clinical Evaluation of Antibiotics in Genital Abscess</i>	1263
<i>J. D. Williams and P. G. Bevan: Rifamide in Biliary Surgery</i>	1267
<i>P. Sharpstone, J. Pickard and R. Williams: Concentrations of Trimethoprim and Sulphamethoxazole in Human Bile</i>	1269
<i>J. L. Honigman: An Antiseptic in an Antibiotic World</i>	1273

## Clinical Evaluation of Antibacterial Chemotherapeutics in Urology

<i>E. Hrádec: Problems, Aims and Possibilities of Chemotherapy in Urology</i>	1279
<i>R. Hoigné, U. Klein and U. Müller: Results of Four-Week Course of Therapy of Urinary Tract Infections. A Comparative Study Using Trimethoprim with Sulfamethoxazole (Bactrim<sup>R</sup> Roche) and Trimethoprim Alone</i>	1283

G. Hitzengerger, H. Pichler and K. H. Spitz: The Problem of Recurrences of Chronic Pyelonephritis after Longerm Treatment with the Combination of Trimethoprim with Sulfamethoxazole . . . . .	1285
A. S. E. Fowle and A. Bye: Concentrations of Trimethoprim and Sulphamethoxazole in Human Prostate Fluid . . . . .	1289
E. Pekarič: Combinations of Trimethoprim and Sulphamethoxazole (Septri) in the Treatment of Urinary Infections of Congenital Origin . . . . .	1291
K. Önen, U. Ülkü and M. Akyüz: Studies with Trimethoprim-Sulphamethoxazole (T-S) (Bactrim) in Urinary Infection . . . . .	1295
E. Hradec, O. Komárek and V. Rosová: Microbial Spectrum of a Modern Urological Department with Special Regard to Effectiveness of Urovalidin . . . . .	1297
Z. Marková, V. Jungmann, V. Želízko and M. Zavadová: Urovalidin in the Treatment of Chronic Urinary Tract Infections . . . . .	1301
J. Fališevac, S. Schönwald and T. Tambić: Our Experience with Gentamicin in Gram-Negative Infections . . . . .	1305
J. Kučera and H. Hlava: Clinical Evaluation of the Combination of Ampicillin with Kanamycin in Enterococcus Urinary Tract Infection . . . . .	1309
P. Brühl: Treatment of Therapy-Resistant Proteus Strains in Obstructive Chronic Pyelonephritis . . . . .	1313
T. Charizanova, Z. Tzenova and I. Torlakov: Antibacterial Activity of Negram and Nibiol as Compared with Some Antibiotics and Chemotherapeutics Used in Practice . . . . .	1315
I. B. Martinek and P. O. H. Wimmer: The Significance of Sulphonamides for the Treatment of Infections of the Urinary Passages . . . . .	1319
T. Charizanova and V. Simova: Combined Application of Ethambutol and Urinary Antiseptics <i>in Vitro</i> and <i>in Vivo</i> . . . . .	1323
A. Hofstetter: Mycoplasma Aetiology of Infections of the Urogenital Tract and Therapeutic Results with Erythromycin . . . . .	1327
H. Gnärpe: Treatment of Human L-Phase Infections of the Urinary Tract . . . . .	1331
W. A. Taylor: The Therapeutic Role of Oral Carbenicillin . . . . .	1333
P. O. Madsen: Comparative Study of Oral Carbenicillin, Ampicillin and Cephaloglycin in Urinary Tract Infections . . . . .	1335
A. K. Knirsch: Clinical Studies with Carbenicillin Indanyl Sodium . . . . .	1337
K. Suzuki, Y. Naide, T. Kawamura, S. Iwata, T. Oda and M. Ohkoshi: Evaluation of Cefazolin in Treating Urinary Tract Infections . . . . .	1341
A. Opitz, H. Knoop, D. Kraft, G. Offermann, K. Schaefer and D. v. Herrath: Treatment of Chronic Kidney Infections with the Cephalosporin Derivative CIBA 36,278-Ba . . . . .	1345
H. Saarimaa, L. Sourander and H. Arvilommi: Treatment of Urinary-Tract Infections with Cephalexin . . . . .	1347
A. W. Kühn, P. Brühl, H. Sous and J. Nijssen: Colistin Clearance in Inhibited Renal Function . . . . .	1351
O. Uhlř, J. Hnátek and M. Halala: Laboratory and Clinical Evaluation of 5-NOK . . . . .	1353
G. Baldauf and G. Simonis: Bacterial Spectrum in a Surgical Hospital: Antibacterial Action of Several Antibiotics with Special Regard to Gentamicin . . . . .	1355
B. Ostojić and V. Marković: Clinical and Laboratory Analysis of the 5-NOK Value in the Treatment of Urinary Infections . . . . .	1357
M. Lee-Jones, Ruth J. Seddon and J. D. Williams: Antibiotics in the Suppression of Catheter-Acquired Urine Infections . . . . .	1361
L. Bernstein-Hahn and M. E. Sember: Chemotherapy of Urinary Infection . . . . .	1363

## Clinical Evaluation of Antibacterial Chemotherapeutics in Dermatovenereology

<i>H. E. Kleine-Natrop, G. Richter, B. Pinzer and G. Sebastian</i> : Present Clinical Position of Some Established Antibacterials in Dermatovenereology . . . . .	1369
<i>Anna Fadrhonicová, K. Dvorský, J. Bílek and J. Krauskopf</i> : Local Treatment of Leg Ulcers by Antibiotics . . . . .	1371
<i>E. From, G. Heydenreich and K. Siboni</i> : Tetracycline Resistant Group G Streptococci in Patients with Leg Sores . . . . .	1375
<i>Y. Asada</i> : Sensitivity Test of <i>Corynebacterium acnes</i> against Antibiotics . . . . .	1379
<i>A. Bissanti, M. Gandola, A. Luvara and L. Mainardi</i> : A Quantitative Evaluation of the Effects of Tetracycline and Rifampicin in Acne vulgaris . . . . .	1383
<i>Y. Privat</i> : The Effect of Sulphamethoxazole-Trimethoprim Combination (Bactrim) on Some Infectious Skin Diseases . . . . .	1387
<i>J. Meyer-Rohn</i> : Trimethoprim-Sulphamethoxazole in Dermato-Venerology . . . . .	1389
<i>Z. Herpay</i> : Therapeutic Effectiveness of Pimafucin Preparations . . . . .	1391
<i>L. J. Caruso</i> : The Effects of Doxycycline and Tetracycline on Fecal Flora . . . . .	1393
<i>Anna Fadrhonicová, E. Geizer, K. Kopecký and F. Záruba</i> : Present Clinical Position of Procain-Penicillin G Injection in the Treatment of Gonorrhea . . . . .	1399
<i>Gunnel Eriksson, L. Magni and J. Wessman</i> : Pharmacological Considerations of the Treatment of Gonorrhea with Oral Ampicillin . . . . .	1401
<i>Gunnel Eriksson and G. Wallmark</i> : Oral Ampicillin in Uncomplicated Gonorrhea . . . . .	1405
<i>R. R. Willcox, K. R. Woodcock and D. Lallo</i> : The Treatment of Gonorrhea with Ampicillin Plus Probenecid in Single Oral Doses . . . . .	1409
<i>J. Lochovský, M. Hejzlar, F. Výmola, V. Dbalý, E. Killnar, J. Weberschinke and V. Sedmidubský</i> : Correlation of Clinico-Laboratory Parameters in the Therapy of Gonorrhea by Penicillin Antibiotics . . . . .	1413
<i>M. Hejzlar, V. Dbalý, J. Lochovský, F. Výmola, J. Danda, J. Weberschinke, V. Sedmidubský and L. Hájková</i> : Correlation of Clinico-Laboratory Parameters in the Therapy of Gonorrhea by Tetracycline and Doxycycline . . . . .	1417
<i>V. Dbalý, M. Hejzlar, J. Lochovský, M. Paroubek, L. Hájková and M. Šafránková</i> : Correlation of Clinico-Laboratory Parameters in the Therapy of Gonorrhea by Spectinomycin . . . . .	1423
<i>B. Nyström and L. Molin</i> : Treatment of Acute Gonorrhea in Patients with Penicillin Allergy . . . . .	1427
<i>K. Tarvainen, A. Lassus and O. V. Renkonen</i> : Treatment of Gonorrhea with 300 mg of Doxycycline on Two Successive Days . . . . .	1429
<i>G. M. Savage</i> : Spectinomycin (Trobicin <sup>(R)</sup> ): A New Antibiotic for the Treatment of Gonorrhea . . . . .	1433

G. Anderson<sup>1</sup>

## The Role of the Laboratory in Antimicrobial Therapy

In this era of specific antimicrobial chemotherapy a major function of the diagnostic microbiology laboratory is not exactly to act as a controlling service in the treatment of microbial disease but rather to serve, as it does, as an important guide to chemotherapy through the intelligent application and interpretation of *in vitro* sensitivity tests in the selection of antimicrobial agents.

Today the minimal inhibitory concentration (MIC) of an antimicrobial agent for a microorganism has precedence over the specific identification of the etiologic agent. This is possibly as it should be, for in certain respects it makes little difference what the specific organism is, providing some agent can be found that will aid in bringing about its eradication. It is not uncommon, therefore, for the physician in considering the possible microbial etiology, in support of his clinical diagnosis, to think of a microorganism in a very general way and excluding viral, rickettsial, fungal, parasitic, or spirochaetal etiology, reflect on the possibility of an etiology that is Gram-positive or negative by nature, and since the microbial agents available today cover in their collective spectrum most, if not all, members within that broad microbial menage that can be separated by the Gram stains, the generalization is acceptable. It is not and should not be used, of course, solely in lieu of definitive laboratory confirmation, identification and, in turn, specific sensitivity information. Jawetz<sup>1</sup>, writing in a light but serious vein, states: "And yet as a first step in rational selection of drugs we must accept the fact that antibiotics are not tonics. Their therapeutic activity depends upon their

ability to inhibit or kill microorganisms. Before administering such a drug the physician must therefore convince himself that the patient suffers from a microbial infection." I would add to that that the organism is sensitive to the agent and, in turn, that the patient is not subject to that physiologic anomaly of being sensitive. Stewart<sup>2</sup> stressed the situation this way: "The intelligent use of antibiotics requires some attention to biology as well as to therapeutic impulses."

The laboratory is considered to be the place where theory is tested, proven to be correct or incorrect, and fact is established. However, methodology with respect to *in vitro* antimicrobial sensitivity testing within the multitude of world-wide laboratories is variable and contains many variables, and there is no *in vivo* testing method short of administration of the chemotherapeutic agent to the patient which, in turn, is guided by some form of an *in vitro* test.

By and large the test most universally used is the simple agar disc diffusion test which in essence had its inception in that momentous observation of Dr. Fleming<sup>3</sup>. However, a test upon the results of which such great responsibility lies, a test with such great potential, is a test which within itself needs guidance. In other words, a reference. I made reference to this need for standardization 12 years ago<sup>4</sup>. I know I was not alone in that desire. The World Health Organization, through Report 210<sup>5</sup>, recognized this need for standardization of antimicrobial sensitivity testing. Today there is still no international reference standard for antimicrobial sensitivity testing by any method that may be used, be it agar diffusion, agar dilution or test tube dilution. Some direct but not completely acceptable progress has been made, parti-

<sup>1</sup> Department of Microbiology, Episcopal Hospital Philadelphia, Pennsylvania, U. S. A.

cularly with respect to the agar disc diffusion method.

The "International Collaborative Study of Antibiotic Sensitivity Testing" (ICS) has been completed and a report has been published<sup>6</sup>. Progress in that study initiated by Dr. Ericsson of the Karolinska sjukhuset, Stockholm, Sweden, sponsored by the World Health Organization and in which scientists in 16 laboratories participated, took time, if for no other reason than the complexities inherent in its scope. Practically all phases of the agar disc diffusion method were scrutinized and comparative data with broth dilution and agar dilution methods collated to provide a basis for a reference standard method in each category. It was not the purpose of the ICS, as has been previously stated<sup>7</sup>, to devise a method for sensitivity testing above all others, but it was the purpose of the ICS to establish acceptable guidelines and make recommendations for reference standards that could be universally applied to antibiotic sensitivity testing. Time permits only a restatement of some of the recommendations pertinent to the ICS and I quote: "The effective application of reference procedures, and improvement in the general quality of the routine performance of *in vitro* sensitivity tests will be dependent in part on the availability of reference laboratories of expert advice and of methods for performance evaluation. Much of this service can best be provided by experienced national laboratories because of differences in technical conventions and of antibiotic usage."

Through the establishment and use of expert or reference laboratories and the combined and cooperative use of experts in microbiology, government agencies controlling chemotherapeutics, pharmaceutical industries and wellinformed experts in clinical infectious diseases, the quality of sensitivity testing in the routine diagnostic laboratory, wherein the greatest problem lies, could be and would be materially elevated. A working basis to bring about this quality control in sensitivity testing would be the reference methods, reference cultures, a reference medium and control of disc performance and potency. The latter is most significant to the success of the program, for which purpose the ICS

recommends the performance standard test of the U. S. Food and Drug Administration. Without control of disc content in the diffusion test, any degree of proper test interpretation, which is so vital, is impossible. I have always believed the antibiotic content of the disc should be optimal to detect organisms that would be considered sensitive, but not of that order to bring into the sensitive range the culture which, by its heterogeneity, should be relegated to that equivocal interpretation of being less than sensitive, but not quite resistant. Apropos to the equivocal interpretive zone referred to by some as "Moderately Resistant", that interpretation should be deleted and the sensitivity of any organism falling into that category should be more specifically determined by the agar dilution or test tube dilution method to afford the physician more specific information, however well he might be able to interpret the significance of the quantitative report versus the qualitative. The determination of sensitivity by the new automated procedures is quantitative which, of course, has merit. However, where the physician has been accustomed to accept the simple term "Sensitive" as probably synonymous with successful therapy, it will take time to orient him to the significance of sensitive to 1.0  $\mu$ g vs. 100  $\mu$ g. We all recognize, of course, the difference in the significance of such a quantitative determination relative to a body site where antimicrobial agents may be concentrated. It would seem well, then, to place the laboratory report in the proper perspective relative to a quantitative report to place some credence in the recommendation of the ICS and think of adopting a categorized report with designations such as Group I, II, III and IV, as it will relate sensitivity more specifically to proper use of the antimicrobial agent. Interpretation and reporting results using the Group scheme was presented early in the antibiotic era by Ericsson and has been in use in Sweden<sup>8</sup>. Its use may require closer cooperation between laboratory and physician, but that aspect of sensitivity testing and interpretation is definitely necessary.

In conclusion, time has permitted only some generalizations on the role of the laboratory as a guide to antimicrobial

chemotherapy. The sensitivity test is that guide. There are many methods with which this can be done. In essence each nation has its own methods which, though similar in most respects, are each intrinsically different, each serving the same purpose to show *in vitro* that the etiologic agent of an infectious disease will be inhibited by a chemotherapeutic agent.

The most widely used method, because of its simplicity and economy, is the agar disc diffusion method. However, there are variables in that method that could account for marked variation in results from one laboratory to another. There is need, then, for standards of reference not only on a national, but on an international basis. Guidelines for standards of reference have been set forth in the Report of an International Collaborative Study of Antibiotic Sensitivity Testing. To expect all to agree would be asking the impossible. Areas such as a medium, disc content, reference cultures and interpretation need further consideration and agreement. There is need for reference laboratories and experts to act collectively to advise, accept and recommend not only the best methods for

testing, but also how the results of those tests may be applied to the greatest advantage for the patient. Experience dictates that what has been done in the laboratory as a guide to chemotherapy deserves meritorious recognition. However, there is always room for improvement.

# References

1. Jawetz E.: Brit. Med. J. 2, 951-955 (1963).
2. Stewart G. T.: Pediat. Clin. N. America, 15, 13 (1968).
3. Fleming A.: Brit. J. exp. Pathol. 10, 226 (1929).
4. Anderson T. G.: Antimicrobial Agents Annual, Plenum Press, Inc.: New York pp. 472-476 (1960).
5. Second Report of the Expert Committee on Antibiotics, World Health Organization Technical Report Series, No. 210, pp. 1-24 (1961).
6. Ericsson H. M., Sherris J. C.: Antibiotic sensitivity testing: Report of an international collaborative study. Acta pathol. microbiol. Scand. B., Suppl. No. 217 (1971).
7. Ericsson H. M., Anderson T. G.: Present status of international standardization of techniques for antibiotic susceptibility tests, pp. 248-250. Georg Thieme-Verlag: Stuttgart (1964).
8. Ericsson H. M., Svartz-Malmberg G.: Antibiot. Chemother. 6, 42-47 (1959).

T. G. A., Episcopal Hospital, Department of Microbiology, Front & Lehigh Avenue, Philadelphia, Pa 19125, U. S. A.



## Application of Sensitivity Discs to Some Clinical Laboratory Tests for Chemotherapy

The sensitivity disc method is now widely used in many laboratories because of its simplicity and availability on multiple drugs. We have studied the disc assay technique as to its usefulness in detecting various attributes of infecting microorganisms and of antimicrobial agents as well as a sensitivity test. The studies have demonstrated the practical usefulness of the technique as a simple test for bacterial development of drug-resistance and for bacterial inactivation of antimicrobial agents<sup>1,2,3</sup>. In this paper we present the results of some subsequent studies.

### 1. Procedural simplification with respect to reading the results of the sensitivity test

While application of the single-disc method in the sensitivity test has the advantage of procedural simplicity, it has the disadvantage that reading the results is inevitably complicated. Using diagrams with translation the diameter of inhibition zone into the degree of sensitivity, we have elaborated a very simple mode for reading the results (Fig. 1). Taking the measures of inhibition zones by means of slide caliper in the usual manner, and, without reading it, we transfer the caliper mark on the diameter directly (arrow) and then record the corresponding degree of sensitivity in order to use the forms as assay data sheets, as they are. This not only permits instant reading of sensitivity (e. g. -, + ..., R. S. ...), but also has the advantage of immediately obtaining the approximate MIC values from a previously prepared calibration chart as well.




Fig. 1. Translation of the diameter of inhibition zone into the degree of sensitivity.

### 2. Simple test for the detection of drug-induced resistance of Staphylococci

Recently, it has been considered clinically important to detect and foresee the possibility of drug-induced resistance before choosing a proper agent or discontinuing it and/or replacing it by an other drug, in the case of treatment with macrolide antibiotics in staphylococcal infections. A simple technique enabled us to detect the phenomenon simultaneously with a number of chemotherapeutic agents.

In our test, a disc of the resistance-inducing drug was placed onto the center of a seeded agar plate. After incubation for 2—3 hours, discs of drugs to be tested were arranged around the central discs in adequate distances, then the plate was further incubated to be read for the formation of inhibition zones. Because of the reduction of the inhibition zone produced by *Staphylococcus* that had acquired resistance to the drug in consequence of contact with the resistance-inducing drug in the centrally placed disc, it was possible to detect readily the development of induced

<sup>1</sup> Department of Internal Medicine, Niigata Railway Hospital, and <sup>2</sup> Department of Pharmacy, Niigata Railway Hospital, Niigata, Japan

resistance (Fig. 2). The results with *Staphylococci* isolated from clinical material, as shown in Table 1, indicated the practical




Fig. 2. Simplified test for the detection of inducible drug-resistance.

E = erythromycin 50  $\mu$ g, Sp = spiramycin 30  $\mu$ g, L = kitasamycin 30  $\mu$ g, OL = oleandomycin 30  $\mu$ g.

usefulness of this simple technique as screening test.

### 3. Simple method for the detection of the transferable drug resistance factor (R) with some strains of enteric bacteria

In the treatment and epidemiology of infections caused by enteric bacteria, it has become important to clarify the state of the transferable resistance factor (R). Detection of the R-factor is usually accomplished by the use of mixed bacterial culture, which is a rather too cumbersome procedure to be adopted for routine labora-





Fig. 3. Streak-seeding method (for detection of transferable drug resistance factor). A growth of the recipient strain ( $R^-$  strain) or that of the donor strain (under test), or both, are seeded by radially streaking on the plate with a sensitivity disc at the center.